LEADER 02351nam 2200565Ia 450 001 9910701781503321 005 20120820140930.0 035 $a(CKB)5470000002420280 035 $a(OCoLC)797208885 035 $a(EXLCZ)995470000002420280 100 $a20120629d2010 ua 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aIntegration assessment of visiting vehicle induced electrical charging of the International Space Station structure$b[electronic resource] /$fLeonard Kramer, Thomas W. Kerslake and Joel T. Galofaro ; prepared for the 11th Spacecraft Charging Technology Conference cosponsored by the Goembel Instruments, SAIC, and Space Systems Loral, Albuquerque, New Mexico, September 20-24, 2010 210 1$aCleveland, Ohio :$cNational Aeronautics and Space Administration, Glenn Research Center,$d[2010] 215 $a1 online resource (10 pages) $ccolor illustrations 225 1 $aNASA/TM ;$v2010-216901 300 $aTitle from title screen (viewed on June 29, 2012). 300 $a"December 2010." 320 $aIncludes bibliographical references (page 10). 606 $aElectric potential$2nasat 606 $aInternational Space Station$2nasat 606 $aMathematical models$2nasat 606 $aSolar arrays$2nasat 606 $aPlasma interactions$2nasat 606 $aSystems engineering$2nasat 606 $aSpace station structures$2nasat 606 $aCrew Exploration Vehicle$2nasat 615 7$aElectric potential. 615 7$aInternational Space Station. 615 7$aMathematical models. 615 7$aSolar arrays. 615 7$aPlasma interactions. 615 7$aSystems engineering. 615 7$aSpace station structures. 615 7$aCrew Exploration Vehicle. 700 $aKramer$b Leonard$01390191 701 $aKerslake$b Thomas W$01386968 701 $aGalofaro$b J$01390192 712 02$aNASA Glenn Research Center. 712 12$aSpacecraft Charging Technology Conference$d(11th :$f2010 :$eAlbuquerque, N.M.) 801 0$bGPO 801 1$bGPO 906 $aBOOK 912 $a9910701781503321 996 $aIntegration assessment of visiting vehicle induced electrical charging of the International Space Station structure$93442726 997 $aUNINA LEADER 03868nam 22007455 450 001 9910300214003321 005 20251116140310.0 010 $a4-431-54487-9 024 7 $a10.1007/978-4-431-54487-6 035 $a(CKB)3710000000311825 035 $a(EBL)1966183 035 $a(OCoLC)908085244 035 $a(SSID)ssj0001408195 035 $a(PQKBManifestationID)11818665 035 $a(PQKBTitleCode)TC0001408195 035 $a(PQKBWorkID)11346220 035 $a(PQKB)10892736 035 $a(DE-He213)978-4-431-54487-6 035 $a(MiAaPQ)EBC1966183 035 $a(PPN)183147154 035 $a(EXLCZ)993710000000311825 100 $a20141203d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aBehçet's Disease $eFrom Genetics to Therapies /$fedited by Yoshiaki Ishigatsubo 205 $a1st ed. 2015. 210 1$aTokyo :$cSpringer Japan :$cImprint: Springer,$d2015. 215 $a1 online resource (183 p.) 300 $aDescription based upon print version of record. 311 08$a4-431-54486-0 320 $aIncludes bibliographical references and index. 327 $a1. Overview -- 2. The Immunopathology of Behcet?s Disease -- 3. Genetics -- 4. Ocular Involvement -- 5. Vascular Involvement of Behçet?s Disease -- 6. Neurological Involvement -- 7. Gastrointestinal Involvement -- 8. Mucocutaneous Manifestations -- 9. Perspective . 330 $aThis book, besides reviewing basic and clinical aspects of Behçet's disease, covers the latest findings, including genetic studies and treatment with biologics for the disease. Although the cause of Behçet's disease is still unknown, it is well known that genetic factors, such as HLA-B51, are involved in its development. Recently, novel susceptibility loci including IL10, IL23R-IL12RB2, and endoplasmic reticulum aminopeptidase 1 have been identified, providing new insights into the pathogenesis of the disease. In addition to basic research, the beneficial efficacy of anti-TNF-alpha monoclonal antibodies has also been suggested for not only uveitis associated with the disease but also other subtypes of the disease such as entero-, vasculo-, and neuro- Behçet's disease. Behçet's Disease:  From Genetics to Therapies  provides essential information both for basic researchers working in the fields of immunology, inflammation, and genetics, and for clinical physicians who are interested in Behçet's disease, such as ophthalmologists, rheumatologists, dermatologists, gastroenterologists, neurologists, and vascular surgeons. 606 $aRheumatology 606 $aAllergy 606 $aDermatology 606 $aOphthalmology 606 $aGastroenterology 606 $aRheumatology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33170 606 $aAllergology$3https://scigraph.springernature.com/ontologies/product-market-codes/H11009 606 $aDermatology$3https://scigraph.springernature.com/ontologies/product-market-codes/H1900X 606 $aOphthalmology$3https://scigraph.springernature.com/ontologies/product-market-codes/H44004 606 $aGastroenterology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33061 615 0$aRheumatology. 615 0$aAllergy. 615 0$aDermatology. 615 0$aOphthalmology. 615 0$aGastroenterology. 615 14$aRheumatology. 615 24$aAllergology. 615 24$aDermatology. 615 24$aOphthalmology. 615 24$aGastroenterology. 676 $a610 676 $a614.5993 676 $a616.33 676 $a616.5 702 $aIshigatsubo$b Yoshiaki$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910300214003321 996 $aBehçet's Disease$91760465 997 $aUNINA